Incorporating ALL Biology into Treatment Decisions: Next Steps toward Targeted Therapy in Adult ALL - PubMed
7 hours ago
- #targeted therapy
- #ALL
- #precision medicine
- Precision medicine is replacing generalized approaches in acute lymphoblastic leukemia (ALL) management, driven by molecular heterogeneity.
- Genomic profiling identifies high-risk subtypes like KMT2A-rearranged, IKZF1-plus BCR::ABL1-positive, BCR::ABL1-like, and TP53-mutant B-cell ALL, requiring tailored therapies.
- Novel strategies such as BH3 mimetics, menin inhibitors, pre-T-cell receptor signaling blockade, and targeted immunotherapy show promise for relapsed/refractory and high-risk groups.
- Emerging challenges include therapy-induced escape mechanisms like lineage switch and antigen loss.
- The future of ALL therapy involves integrating biology-driven approaches to improve outcomes across all ages.